London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]
Company news
Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]
02 July 2019
We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]
26 April 2019
Pulmocide announces the initiation of a double-blind, placebo-controlled study to evaluate the effects of PC945 on fungal burden in a moderate-severe asthma population with Aspergillus fumigatus infection. PC945 will be […]
17 January 2019
Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled […]
20 March 2017